S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer

This phase III trial studies how well carvedilol works in preventing cardiac toxicity in
patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has
spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat
heart failure and high blood pressure, and it may prevent the heart from side effects of
chemotherapy.

Intervention

Carvedilol, Laboratory Biomarker Analysis, Patient Observation

Condition

Cardiotoxicity, HER2/Neu Positive, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7

Investigators

Justin Floyd, Ashkan Bahrani, Krishna S. Gunturu, Joan L. Kramer, Shelly S. Lo, Bryan A. Faller, Erin F. Cobain, Frank J. Brescia, Sunitha Vemulapalli, Jay W. Carlson, Cynthia M. Vakhariya, Kathleen J. Yost, Sailendra Vasireddy, Sung Ho B. Lee, Richard L. Deming, Barbara S. Craft, Halle C. Moore, David M. King, Hadeel Assad, Joanne E. Mortimer, John T. Cole, David S. Hanson, Cheryl F. Jones, Katherine D. Crew, Gregory A. Masters, Martine Extermann, Abdul Hai Mansoor, Anne P. O'Dea, Iftekhar A. Khan, Andrew W. Pippas, Charles H. Nash, John M. Schallenkamp, Gina G. Chung, Thomas E. Lad, Jacklyn M. Nemunaitis, Naveed A. Rana, Bonni L. Guerin, Rachel L. Yung, Lisa Bailey, Josh D. Simmons, Yadyra Rivera, Kathryn M. Leininger, Ki Y. Chung, Charles W. Drescher, Hassan I. Tahsildar, Keun Seok Lee, Priya Jayachandran, Alison E. Spellman, Marshall P. Stagg, Tareq Al Baghdadi, Haythem Y. Ali, Dan Costin, Bahar Moftakhar, Mahmoud Charif, Alexandra d. Zimmer, Monali K. Vasekar, Joyson Poulose, Vlad G. Zaha, Robert M. Kyler

See list of participating sites